Pharmaceutical companies should deploy cash to fund struggling biotech companies, which could generate much needed new drugs.
Advertisement
The Scientist
Most Recent
How to successfully surmount the challenges women face in becoming biotech industry leaders
Celebrity spokespeople for pharma companies can manipulate the public’s understanding of disease.
The agency releases draft guidelines on unsolicited questions about off-label use, but leaves many questions about social media marketing unanswered.
A roundup of eight biotech companies that didn’t make it through this year's continuing tough economic times
Research universities are removing the licensing fees they charged industry companies for working with their scientists.
Some Big Pharma companies are turning to the world’s automobile makers for advice on innovation and profitability.
The pharmaceutical darling that has brought billions in revenue to Pfizer over the past 15 years will now share the shelves with its generic competitors.
Pharmacovigilance must keep pace with global distribution of drugs in resource-limited settings.
With mounting interest from biotechs, Big Pharma, and the federal government, research on rare diseases is burgeoning.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
